Tonix Pharmaceuticals’ Investigational New Drug (IND) application for starting a Phase II clinical trial of TNX-102 SL for Long Covid-19 was granted clearance by the US Food and Drug Administration (FDA).

The randomised, double-blind, placebo-controlled Phase II trial of TNX-102 is anticipated to commence in the second quarter of this year.

It will assess the safety and efficacy of a 5.6mg daily sublingual dose of TNX-102 to treat Long Covid patients having pain at various sites. 

To be carried out at nearly 30 clinical centres, the trial will enrol around 470 patients.

These participants will be divided into a 1:1 ratio to receive TNX-102 SL or placebo for 14 weeks. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

See Also:

Change from baseline in the weekly average of daily self-reported worst pain intensity scores at week 14 is the trial’s primary efficacy endpoint.

An interim assessment will be carried out on enrolling the first half of trial subjects for potential re-estimation of the sample size.

Tonix Pharmaceuticals CEO Seth Lederman said: “We are excited to have received the FDA’s IND clearance to begin clinical trials of TNX-102 SL for the treatment of Long Covid. 

“Our study will focus on testing TNX-102 SL in the treatment of patients with multi-site pain associated with Long Covid.” 

In July last year, the company announced the halting of subject enrolment in the Phase III RALLY trial of 5.6mg TNX-102 SL for fibromyalgia management.

The move comes after the Independent Data Monitoring Committee carried out an unblinded, pre-planned interim assessment of the initial 50% of study subjects and advised trial suspension due to futility.